Details
Stereochemistry | RACEMIC |
Molecular Formula | C23H28N2O3.C3H4O4 |
Molecular Weight | 484.5415 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)=O.CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
InChI
InChIKey=LDOONRJGLKHGJI-UHFFFAOYSA-N
InChI=1S/C23H28N2O3.C3H4O4/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17;4-2(5)1-3(6)7/h5-13,18,24-25H,14-15H2,1-4H3;1H2,(H,4,5)(H,6,7)
Molecular Formula | C23H28N2O3 |
Molecular Weight | 380.48 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C3H4O4 |
Molecular Weight | 104.0615 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11314603 | https://www.ncbi.nlm.nih.gov/pubmed/1706984
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11314603 | https://www.ncbi.nlm.nih.gov/pubmed/1706984
Bopindolol (4-[benzoyloxy-3-tertbutylaminopropoxy]-2-methylindole hydrogen malonate) is an indole beta-adrenoceptor antagonist bearing a benzoyl ester residue on the beta-carbon atom of the propanolamine side chain. Bopindolol is metabolized by esterase to benzoic acid and an active metabolite, 18-502
[4-(3-t-butylamino-2-hydroxypropoxy)-2-methyl indole], which is further metabolized to
20-785 [4-(3-t-butylaminopropoxy)-2-carboxyl indole]. Bopindolol produces sustained blockade of beta 1- and beta 2-adrenoceptors, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Bopindolol is used in the treatment of hypertension. In limited trials bopindolol has also successfully reduced symptoms in patients with angina pectoris, anxiety and essential tremor.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11314603 |
7.44 null [pKi] | ||
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11314603 |
7.33 null [pKi] | ||
Target ID: CHEMBL273 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11314603 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BOPINDOLOL Approved UseBopindolol is a nonselective beta-adrenoceptor antagonist with partial agonist activity which is used in the treatment of hypertension. |
PubMed
Title | Date | PubMed |
---|---|---|
Beta-blockers and psychic stress: a double-blind, placebo-controlled study of bopindolol vs lorazepam and butalbital in surgical patients. | 1985 Sep |
|
Bopindolol: pharmacological basis and clinical implications. | 2001 Spring |
|
Transdermal delivery of beta-blockers. | 2006 May |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1706984
antihypertensive effects of bopindolol 0.5 to 4 mg are sustained for more than 24 hours after once daily dosing
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:27:18 GMT 2023
by
admin
on
Fri Dec 15 17:27:18 GMT 2023
|
Record UNII |
S3UWR70991
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
76749
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
SUB00852MIG
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
DTXSID501002965
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL357995
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
236903
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000091995
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
636368
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
m2605
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
S3UWR70991
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
82857-38-3
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |